Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 1/20 | 0.46 |
| ▸ | CCNK | O75909 | 8/20 | 0.41 |
| ▸ | CDK9 | P50750 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KAT7 | O95251 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747535 | 0.79 | CDK9 (0.65) | EIF4ECCNKCDK9 | |
| SCHEMBL21747510 | 0.77 | AOC2 (0.35) | EIF4ENPC1RAB9A | |
| SCHEMBL21747536 | 0.74 | CPB1 (0.45) | EIF4ECYP3A4CYP19A1 | |
| SCHEMBL21747560 | 0.71 | CCNK (0.54) | CCNKCDK9 | |
| SCHEMBL23125459 | 0.70 | USP30 (0.43) | CCNKCDK9CYP3A4ROCK1 | |
| SCHEMBL21747543 | 0.69 | CCNK (0.52) | CCNKCDK9NPC1RAB9A | |
| SCHEMBL2389573 | 0.65 | VCP (0.44) | IRAK4 | |
| SCHEMBL28551860 | 0.65 | ALDH1A1 (0.61) | RAB9A | |
| SCHEMBL17180758 | 0.65 | EIF4E (0.81) | EIF4ECYP3A4 | |
| SCHEMBL19328188 | 0.64 | GSK3B (0.44) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | EIF4E 1345/4885CCNK 14/4885CDK9 1/4885 |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | CDK9, CDK19, CDKL1 | EIF4E 1684/4885CCNK 17/4885CDK9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.